Indian pharma exports grow at 18% to $24.44 billion in FY 21 from $20.58 bn

Pharma exports from India

witnessed over 18 per cent growth to USD 24.44 billion during the last financial year against USD 20.58 billion in FY20, Pharmaceuticals Export Promotion Council of India (Pharmexcil) said on Saturday.

“We have observed a big leap in our exports in the month of March 2021 which is USD 2.3 billion (figures for March are provisional) and is highest among the exports of all the months of this financial year, the growth rate for this month is 48.5 per cent against the exports in March 2020 (USD 1.54 billion),” Udaya Bhaskar, Director General of Pharmexcil said in a release.

Growth rate seems relatively big as the exports of March 2020 was crunched due to lockdown across the world and supply chain disruption, he was quoted as saying.

When the global pharma market is negatively grown by 1-2 per cent in 2020, there is a big surge in demand for Indian made generics owing to its quality and affordability, the official said adding Drug formulations and Biologicals is the second largest Principal commodity being exported by India.

The Pharma exports body is expecting big growth in Indian vaccine exports in the coming years and the government policy on PLI (production Linked Incentive) scheme will also help the domestic pharma to grow by reducing import dependence and develop export potential in the days to come as most of the countries are looking at India for APIs ( active pharmaceutical ingredient) he said.

North America is the largest exporting region for Indian pharmaceuticals with more than 34 per cent share.

Country wise exports to the US, Canada and Mexico have recorded a growth of 12.6, 30 and 21.4 per cent respectively.

South Africa being the second largest exporting country, recorded a big jump of 28 per cent growth while Europe was the third largest exporting region which has recorded approximately 11 per cent growth over previous year.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.


We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor